STAAR Surgical Co. 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 28, 2002. STAAR Surgical Company develops, manufactures, and distributes medical devices for minimally invasive ophthalmic surgery, primarily intraocular lenses (IOLs) for cataract, refractive, and glaucoma segments. The company operates globally with manufacturing sites in the United States and Switzerland.
Key Financial Metrics
| Metric | Three Months Ended June 28, 2002 | Six Months Ended June 28, 2002 |
|---|---|---|
| Total Revenues | $12.1 million | $23.8 million |
| Gross Profit | $6.0 million (49.8% margin) | $11.7 million (49.3% margin) |
| Operating Loss | $(3.0) million | $(4.7) million |
| Net Loss | $(3.9) million | $(4.9) million |
| Cash and Equivalents | $0.6 million | $0.6 million (Ending Balance) |
| Notes Payable | $8.2 million | $8.2 million |
| Current Ratio | 1.8:1 | 1.8:1 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 6.2% for the quarter and 8.0% for the six-month period compared to 2001. This was driven by lower sales from closed foreign subsidiaries, decreased average selling prices for silicone and Collamer IOLs, and lower unit sales in the U.S.
- Margin Improvement: Despite lower sales, gross profit margins improved significantly (from 14.5% to 49.8% for the quarter) due to the absence of one-time inventory write-downs recorded in the prior year. However, cost of sales as a percentage of revenue increased slightly due to higher unit costs of inventory manufactured during low-volume periods.
- Expense Reduction: Marketing and selling expenses decreased by 19.5% (quarter) and 20.4% (six months) due to cost containment and subsidiary closures. General and administrative expenses decreased slightly in absolute dollars due to the elimination of goodwill amortization following the adoption of SFAS 142.
- Unusual Items: The company recorded $1.2 million in subsidiary closure charges related to the sale of its South African subsidiary and closure of its Swedish subsidiary. These charges were primarily foreign currency translation losses previously held in equity.
Outlook, Risks, and Management Commentary
- Liquidity and Debt Restructuring: The company was not in compliance with certain loan covenants during the quarter. A restated credit agreement effective July 31, 2002, reduced the loan amount from $7.0 million to $4.5 million and released $2.0 million of restricted cash to pay down the note. Management believes available credit and cash balances are sufficient for the next nine months.
- Future Profitability: Management expects gross profit to improve for the remainder of the year as high-cost inventory is sold off. The company anticipates future profitability but notes that realization of deferred tax assets depends on generating sufficient future taxable income.
- Risks: Key risks include foreign currency fluctuations (as the company does not hedge), regulatory changes, and the need to generate sufficient income to utilize tax loss carryforbacks. Legal proceedings involving former executives and consultants remain ongoing or recently settled.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the status of the renegotiated credit agreement and the company's ability to meet the new monthly reduction requirements through February 2003.
- Inventory Valuation: Confirm the extent to which high-cost inventory has been sold and the projected timeline for margin normalization.
- Cash Position: Monitor the low cash balance ($0.6 million) against the $8.2 million in notes payable and the upcoming debt reduction schedule.
- Legal Contingencies: Review the status of the settlement with William D. Kray ($150,000) and the bankruptcy claim against Andrew F. Pollet ($2.7 million).
- Tax Refund: Track the expected receipt of the $959,000 tax refund filed in Q2 2002.